The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass.
Open accessAbstract
Micropuncture and morphologic studies were performed in four groups of male Munich-Wistar rats after removal of the right kidney and segmental infarction of two-thirds of the left kidney. Groups 1 and 3 received no specific therapy. Groups 2 and 4 were treated with the angiotensin I converting enzyme inhibitor, enalapril, 50 mg/liter of which was put in their drinking water. All rats were fed standard chow. Groups 1 and 2 underwent micropuncture study 4 wk after renal ablation. Untreated group 1 rats exhibited systemic hypertension and elevation of the single nephron glomerular filtration rate (SNGFR) due to high average values for the mean glomerular transcapillary hydraulic pressure difference and glomerular plasma flow rate. In group 2 rats, treatment with enalapril prevented systemic hypertension and maintained the mean glomerular transcapillary hydraulic pressure gradient at near-normal levels without significantly compromising SNGFR and the glomerular capillary plasma flow rate, as compared with untreated group 1 rats. Groups 3 and 4 were studied 8 wk after renal ablation. Untreated group 3 rats demonstrated persistent systemic hypertension, progressive proteinuria, and glomerular structural lesions, including mesangial expansion and segmental sclerosis. In group 4 rats, treatment with enalapril maintained systemic blood pressure at normal levels over the 8-wk period and significantly limited the development of proteinuria and glomerular lesions. These studies suggest that control of glomerular hypertension effectively limits glomerular injury in rats with renal ablation, and further support the view that glomerular hemodynamic changes mediate progressive renal injury when nephron number is reduced.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blantz, R. C., Konnen, K. S., & Tucker, B. J. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108293 · Cited by 428
Cited by
Renal Autoregulation in Health and Disease
Carlström, M., Wilcox, C. S., & Arendshorst, W. J. (2015) · Physiological Reviews · doi:10.1152/physrev.00042.2012 · Cited by 485
Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists
Taal, M. W., & Brenner, B. M. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00031.x · Cited by 439
Self-citationFocal and segmental glomerulosclerosis: Analogies to atherosclerosis
Diamond, J. R., & Karnovsky, M. J. (1988) · Kidney International · doi:10.1038/ki.1988.87 · Cited by 330
The podocyte slit diaphragm--from a thin grey line to a complex signalling hub
Grahammer, F., Schell, C., & Huber, T. B. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.169 · Cited by 269
Cortinovis, M., Perico, N., Ruggenenti, P., Remuzzi, A., & Remuzzi, G. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00559-y · Cited by 214
Angiotensin II Activates Collagen I Gene Through a Mechanism Involving the MAP/ER Kinase Pathway
Tharaux, P.-L., Chatziantoniou, C., Fakhouri, F., & Dussaule, J.-C. (2000) · Hypertension · doi:10.1161/01.hyp.36.3.330 · Cited by 173
Modulation of glomerular hypertension defines susceptibility to progressive glomerular injury
Simons, J. L., Provoost, A. P., Anderson, S., Rennke, H. G., Troy, J. L., & Brenner, B. M. (1994) · Kidney International · doi:10.1038/ki.1994.287 · Cited by 83
Self-citationCircadian rhythm of blood pressure and the renin-angiotensin system in the kidney
Ohashi, N., Isobe, S., Ishigaki, S., & Yasuda, H. (2017) · Hypertension Research · doi:10.1038/hr.2016.166 · Cited by 78
(1990) · PubMed · Cited by 69
Lambers Heerspink, H. J., Weldegiorgis, M., Inker, L. A., Gansevoort, R., Parving, H.-H., Dwyer, J. P., Mondal, H., Coresh, J., Greene, T., Levey, A. S., et al. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.09.016 · Cited by 69
Effects of renin–angiotensin system blockade in the aging kidney
Ferder, L. (2003) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00264-4 · Cited by 52
Adenosine in renin-dependent renovascular hypertension.
Ohnishi, A., Li, P., Branch, R. A., Biaggioni, I. O., & Jackson, E. K. (1988) · Hypertension · doi:10.1161/01.hyp.12.2.152 · Cited by 28
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
“A prespecified secondary analysis of SELECT participants without diabetes showed that semaglutide reduced the composite kidney endpoint by 22% (86), with 75% of participants on RAAS blocker therapy at baseline.”
Influential
Metadata
- Authors
- Anderson, S., Meyer, T. W., Rennke, H. G., & Brenner, B. M.
- Venue
- Journal of Clinical Investigation
- Published
- 1985-08-01
- Volume
- 76
- Issue
- 2
- Pages
- 612-619
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2063928700
- Cited by
- 932
- References
- 1
- FWCI
- 36.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.